Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-17
2008-10-14
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S045000, C128S200230
Reexamination Certificate
active
07435720
ABSTRACT:
Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
REFERENCES:
patent: 4511069 (1985-04-01), Kalat
patent: 5164368 (1992-11-01), Recker
patent: 5578567 (1996-11-01), Cardinaux et al.
patent: 5952008 (1999-09-01), Backstrom et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6416503 (2002-07-01), Suzuki et al.
patent: 6472505 (2002-10-01), Condon et al.
patent: 6590081 (2003-07-01), Zhang et al.
patent: 6756480 (2004-06-01), Kostenuik et al.
patent: 6977070 (2005-12-01), Dugger et al.
patent: 6977077 (2005-12-01), Hock et al.
patent: 2003/0039654 (2003-02-01), Kostenuik et al.
patent: 2003/0059376 (2003-03-01), Libbey, III et al.
patent: 2004/0077540 (2004-04-01), Quay
patent: 2005/0123509 (2005-06-01), Lehrman et al.
patent: 2005/0203002 (2005-09-01), Tzannis et al.
patent: 2005/0215475 (2005-09-01), Ong et al.
patent: 2006/0052306 (2006-03-01), Costantino et al.
patent: 2006/0062758 (2006-03-01), Cui et al.
patent: 2006/0189533 (2006-08-01), Quay et al.
patent: 0747054 (1996-12-01), None
patent: 0878201 (1998-11-01), None
patent: 0643981 (1999-11-01), None
patent: 5238929 (1993-09-01), None
patent: 10130171 (1998-05-01), None
patent: WO 99055310 (1999-11-01), None
patent: WO 2005027978 (2005-03-01), None
patent: WO 2005051456 (2005-06-01), None
patent: WO 2005115441 (2005-12-01), None
FDA's CDRH Final Guidance for Neublizers, Metered Dose Inhalers, Spacers, and Actuators (issued on Oct. 1, 1993), pp. 1-12 (also available on the Internet at www.fda.gov/cdrh/ode/784.html).
Codrons, V.; Vanderbist, F.; Verbeeck, R. K.; Arras, M.; Lison, D.; Preat, V. and Vanbever, R., “Systemic Delivery of Parathyroid Hormone (1-34) Using Inhalation Dry Powders in Rats,”Journal of Pharmaceutical Sciences, May 2003:92 (5) pp. 938-950.
Newman, S. P.; Pitcairn, G.R.; and Dalby, R.N., “Drug Delivery to the Nasal Cavity: In vitro and In Vivo Assessment,”Critical Review of Therapeutic Drug Carrier Systems, 2004: 21 (1) pp. 21-66.
Costantino Henry R.
Kleppe Mary S.
Li Ching-Yuan
Quay Steven C.
Bales Mark A.
MDRNA, Inc.
Nickol Gary B.
Woodward Cherie M
LandOfFree
Compositions and methods for enhanced mucosal delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhanced mucosal delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhanced mucosal delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994306